NetworkNewsBreaks – Volition Solves Liquid Biopsy’s “Needle in a Haystack” Problem; Achieves 180-fold (18,000%) Enrichment
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced the preprint release of research introducing Capture-Seq(TM), a new method for analyzing transcription factor–protected ultrashort DNA fragments in blood as potential low-cost cancer biomarkers. The manuscript, titled “Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq,” highlights Volition’s achievement of 180-fold enrichment of transcription factor–bound fragments by focusing on DNA in its natural chromosomal context rather than on chemically extracted DNA, overcoming the longstanding challenge of overwhelming background DNA in liquid biopsy testing. Early findings from a 70-person training cohort showed 100 percent sensitivity and 100 percent…
